Q&A: BARDA Director Rick Bright Discusses New Programs, Focus on Diagnostics

Sep 30, 2019

|

Premium

NEW YORK – Rick Bright joined the Biomedical Advanced Research and Development Authority in 2010 following a scientific career addressing influenza at the US Centers for Disease Control and Prevention and at PATH, plus a stint in industry at a vaccine development firm.

Now a 12-year-old agency, BARDA was always intended to be nimble and innovative. Lately, however, Bright has been revving it up further, striving to create new funding mechanisms that are even faster and more ingenious — qualities he noted are more typically associated with industry than government.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Moving Forward With Migrant DNA Collection Plans

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher Dies

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Just Another Diet

A Washington Post columnist writes that she is skeptical about DNA-based diets.

PNAS Studies Tackle GI Tumors, GenBank, Lung Cancer Mouse Models

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.

Featured White Papers

Analytical Validation of the Oncomine Pan-Cancer Cell-Free Assay

A High-Performance Solution Combining CleanPlex OncoZoom Cancer Hotspot Panel and SOPHiA AI for Rapid Characterization of Somatic Mutations

Benchmarking of the Microsart AMP Mycoplasma Kit with Products of Two Other Suppliers

Genetic Testing as a Tool for Improving Care and Outcomes for Patients with Rare Inherited Retinal Diseases

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov

04

Featured Webinar

Digital Solutions for NGS Genotyping – Accuracy, Clinical Relevancy, and Report Generation

This webinar will provide a look at how the Institute of Hematopathology in Hamburg, Germany, is implementing complex genomic testing for lung cancer.

Nov

13

Featured Webinar

Targeted Detection of MET and NTRK Oncogenic Variants in Routine Molecular Analysis

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.

Nov

14

Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Menu